Published :
Tables : 46
Figures : 43
Category : Healthcare
No. of Pages : 216
Report Code : HC-U2083
Multiple Sclerosis Drugs Market is poised to register a CAGR of 3.9% during the forecast period 2022 to 2028. MS is a neurological disorder that causes disability almost universally. Multiple sclerosis is an inflammatory, chronic, and autoimmune disease of the central nervous system that affects the brain's communication with different parts of the body. In this autoimmune disease, the protective myelin sheath surrounding neurons is damaged, causing communication to and from the brain to be disrupted. As a result of such lesions, control of bodily functions is impaired and clinical disabilities may result. A number of types of MS have been recognized, such as relapsing-remitting, clinically isolated syndrome, primary progressive, and secondary progressive, characterized by varying rates of relapses and disability progression. In order to diagnose multiple sclerosis (MS), the majority of evidence comes from clinical findings and supporting tests, such as magnetic resonance imaging (MRI) of the brain and cerebrospinal fluid examination. MS usually develops among young adults between the ages of 29 and 33, and women are more likely to be affected than men. Despite the incomplete understanding of MS etiology, it is interesting to note that the prevalence of MS varies by geography and ethnicity. It has also been suggested that those exposed to adequate sunlight and subsequent production of vitamin D may be less likely to develop multiple sclerosis. Several pharmaceutical companies are currently conducting clinical studies to treat multiple sclerosis. A number of companies are developing new medicines for treating multiple sclerosis radiology, which is helping to drive the market's growth. The high cost of medication used to treat multiple sclerosis (MS) limits the growth of the MS drug market. There is a high risk of impairment associated with multiple sclerosis, which necessitates lifetime therapy. FutureWise Market Research has illustrated a report on the that provides an in-depth anatomy of Multiple Sclerosis Drugs market trends affecting its growth. Moreover, it includes intricate insights on profitability graph, Multiple Sclerosis Drugs market share, SWOT analysis and geographical augmentation of this business. Furthermore, the report provides information on the status of key market players in the competitive landscape analysis of the market. The Multiple Sclerosis Drugs market is projected to achieve significant growth by the end of the forecast period as per the research study conducted by FutureWise research analysts. The report explains that this business is predicted to record a remarkable growth rate over the forecast period. This report provides important information regarding the total valuation that this industry holds presently and it also lists the segmentation of the Multiple Sclerosis Drugs market along with the growth opportunities present across this business vertical. Major players included in the Multiple Sclerosis Drugs market are • Biogen • Teva Pharmaceutical • Merck KGaA • Novartis • Bayer • Sanofi • Acorda Therapeutics • Questcor Pharmaceuticals • Pfizer • Merck & Co • F.Hoffmann-La Roche Ltd • Bristol (Note: The list of the major players will be updated with the latest market scenario and trends) Multiple Sclerosis Drugs Market Segmentation: By Drug Class • Immunomodulators • Immunosuppressants • Interferons • Others By Route of Administration • Oral • Injection • Intramuscular • Subcutaneous • Intravenous By Distribution Channel • Hospital Pharmacy • Retail Pharmacy • Online Pharmacy By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Multiple Sclerosis Drugs Market Video Sample: Competitive Landscape: Tier 1 players- established companies in the market with a major market share Tier 2 players Emerging players which are growing rapidly New Entrants FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the Multiple Sclerosis Drugs market by drug class, by route of administration, by distribution channel and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions — North America, Europe, Asia Pacific, Latin America and Middle East and Africa. To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization services offered are free of charge with purchase of any license of the report. You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
MS is a neurological disorder that causes disability almost universally. Multiple sclerosis is an inflammatory, chronic, and autoimmune disease of the central nervous system that affects the brain's communication with different parts of the body. In this autoimmune disease, the protective myelin sheath surrounding neurons is damaged, causing communication to and from the brain to be disrupted. As a result of such lesions, control of bodily functions is impaired and clinical disabilities may result. A number of types of MS have been recognized, such as relapsing-remitting, clinically isolated syndrome, primary progressive, and secondary progressive, characterized by varying rates of relapses and disability progression. In order to diagnose multiple sclerosis (MS), the majority of evidence comes from clinical findings and supporting tests, such as magnetic resonance imaging (MRI) of the brain and cerebrospinal fluid examination. MS usually develops among young adults between the ages of 29 and 33, and women are more likely to be affected than men. Despite the incomplete understanding of MS etiology, it is interesting to note that the prevalence of MS varies by geography and ethnicity. It has also been suggested that those exposed to adequate sunlight and subsequent production of vitamin D may be less likely to develop multiple sclerosis. Several pharmaceutical companies are currently conducting clinical studies to treat multiple sclerosis. A number of companies are developing new medicines for treating multiple sclerosis radiology, which is helping to drive the market's growth. The high cost of medication used to treat multiple sclerosis (MS) limits the growth of the MS drug market. There is a high risk of impairment associated with multiple sclerosis, which necessitates lifetime therapy.
FutureWise Market Research has illustrated a report on the that provides an in-depth anatomy of Multiple Sclerosis Drugs market trends affecting its growth. Moreover, it includes intricate insights on profitability graph, Multiple Sclerosis Drugs market share, SWOT analysis and geographical augmentation of this business. Furthermore, the report provides information on the status of key market players in the competitive landscape analysis of the market.
The Multiple Sclerosis Drugs market is projected to achieve significant growth by the end of the forecast period as per the research study conducted by FutureWise research analysts. The report explains that this business is predicted to record a remarkable growth rate over the forecast period. This report provides important information regarding the total valuation that this industry holds presently and it also lists the segmentation of the Multiple Sclerosis Drugs market along with the growth opportunities present across this business vertical.
Major players included in the Multiple Sclerosis Drugs market are
• Biogen • Teva Pharmaceutical • Merck KGaA • Novartis • Bayer • Sanofi • Acorda Therapeutics • Questcor Pharmaceuticals • Pfizer • Merck & Co • F.Hoffmann-La Roche Ltd • Bristol
(Note: The list of the major players will be updated with the latest market scenario and trends)
Multiple Sclerosis Drugs Market Segmentation:
By Drug Class • Immunomodulators • Immunosuppressants • Interferons • Others
By Route of Administration • Oral • Injection • Intramuscular • Subcutaneous • Intravenous
By Distribution Channel • Hospital Pharmacy • Retail Pharmacy • Online Pharmacy
By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
Multiple Sclerosis Drugs Market Video Sample:
Competitive Landscape:
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Multiple Sclerosis Drugs Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Multiple Sclerosis Drugs Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Multiple Sclerosis Drugs Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Multiple Sclerosis Drugs Market, By Drug Class Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Immunomodulators 7.2. Immunosuppressants 7.3. Interferons 7.4. Others 8. Multiple Sclerosis Drugs Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Oral 8.2. Injection 8.3. Intramuscular 8.4. Subcutaneous 8.5. Intravenous 9. Multiple Sclerosis Drugs Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Hospital Pharmacy 9.2. Retail Pharmacy 9.3. Online Pharmacy 10. North America Multiple Sclerosis Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America Multiple Sclerosis Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe Multiple Sclerosis Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific Multiple Sclerosis Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. Biogen 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Teva Pharmaceutical 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. Merck KGaA 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Novartis 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Bayer 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. Sanofi 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Acorda Therapeutics 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Questcor Pharmaceuticals 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Pfizer 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10. Merck & Co 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11. F.Hoffmann-La Roche Ltd 16.11.1. Company Overview 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12. Bristol 16.12.1. Company Overview 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview 17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations 18. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Multiple Sclerosis Drugs Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Multiple Sclerosis Drugs Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Multiple Sclerosis Drugs Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Multiple Sclerosis Drugs Market, By Drug Class Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Immunomodulators 7.2. Immunosuppressants 7.3. Interferons 7.4. Others
8. Multiple Sclerosis Drugs Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Oral 8.2. Injection 8.3. Intramuscular 8.4. Subcutaneous 8.5. Intravenous
9. Multiple Sclerosis Drugs Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Hospital Pharmacy 9.2. Retail Pharmacy 9.3. Online Pharmacy
10. North America Multiple Sclerosis Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028
11. Latin America Multiple Sclerosis Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028
12. Europe Multiple Sclerosis Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028
13. Asia Pacific Multiple Sclerosis Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028
15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. Biogen 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Teva Pharmaceutical 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. Merck KGaA 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Novartis 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Bayer 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. Sanofi 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Acorda Therapeutics 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Questcor Pharmaceuticals 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Pfizer 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10. Merck & Co 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11. F.Hoffmann-La Roche Ltd 16.11.1. Company Overview 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12. Bristol 16.12.1. Company Overview 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview
17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics